South Korea · Delayed Price · Currency is KRW Qurient Company Description
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally.
The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM.
Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors.
The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011.
Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
| Country | South Korea |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 31 |
| CEO | Ki-Yean Nam |
Contact Details
Address: C-dong 801 Seongnam-si, 13487 South Korea | |
| Phone | 82 31 8060 1600 |
| Website | qurient.com |
Stock Details
| Ticker Symbol | 115180 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ki-Yean Nam | Chief Executive Officer |
| Chang Eyun Yu | Chief Financial Officer |